Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 May;11(5):1731-1733.
doi: 10.21037/jtd.2019.05.38.

Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis

Luis Jara-Palomares  1   2 , Samira Marin-Romero  1 , María Isabel Asensio-Cruz  1   2 , Teresa Elias-Hernandez  1 , Remedios Otero-Candelera  1   2
Affiliations
Editorial

Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis

Luis Jara-Palomares et al. J Thorac Dis. 2019 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Jara-Palomares reports speaker bureau from Bayer Hispania, Actelion, Rovi, PFIZER, Menarini, and from Leo-Pharma, outside the submitted work; Research funding Leo-Pharma. Dr. Elias-Hernandez reports Honoraria for lectures: MSD; Honoraria for advisory boards activities: Bayer Heathcare, Sanofi; Fees from Bayer Healthcare, GSK, Actelion. Dr. Otero-Candelera: Honoraria for lectures Actelion, Leo-Pharma, Bayer Healthcare, MSD, Sanofi Honoraria for advisory board activities Actelion, Bayer Heathcare, MSD, Sanofi Research funding Bayer Heathcare, Leo-Pharma; Fees: Actelion, Bayer Heathcare, MSD, Leo Pharma. The other authors have no conflicts of interest to declare.

Comment on

  • Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.
    Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, Mandourah Y, Almekhlafi GA, Almaani M, Al Bshabshe A, Finfer S, Arshad Z, Khalid I, Mehta Y, Gaur A, Hawa H, Buscher H, Lababidi H, Al Aithan A, Abdukahil SAI, Jose J, Afesh LY, Al-Dawood A; Saudi Critical Care Trials Group. Arabi YM, et al. N Engl J Med. 2019 Apr 4;380(14):1305-1315. doi: 10.1056/NEJMoa1816150. Epub 2019 Feb 18. N Engl J Med. 2019. PMID: 30779530 Clinical Trial.

References

    1. Office of the Surgeon General (US); National Heart, Lung, and Blood Institute (US). The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville (MD): Office of the Surgeon General (US); 2008. Available online: https://www.ncbi.nlm.nih.gov/books/NBK44178/. Accessed May 20, 2019. - PubMed
    1. Alhazzani W, Lim W, Jaeschke RZ, et al. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013;41:2088-98. 10.1097/CCM.0b013e31828cf104 - DOI - PubMed
    1. Ginzburg E, Dujardin F. Physicians' perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey. J Thromb Thrombolysis 2011;31:188-95. 10.1007/s11239-010-0498-9 - DOI - PubMed
    1. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009;120:2006-11. 10.1161/CIRCULATIONAHA.109.872630 - DOI - PubMed
    1. Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;155:625-32. 10.7326/0003-4819-155-9-201111010-00011 - DOI - PubMed